Hospital
Lancaster Hospital Corporation
Lancaster Hospital Corporation was paid $108.63M by Medicaid between Jan 2018 and Dec 2024, across 242 billing codes. Its largest line is 0450, Emergency room services — 39% of everything it billed.
33Billing provider infoLANCASTER HOSPITAL CORPORATION
PALMDALE, CA 93551
PALMDALE, CA 93551
33aNPI1508856535assigned 10/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$108.63M
24GClaims1,484,782
24DCodes billed242
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#17 of 410
Median peer was paid$6.90M
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 246,967 | $14.26M | |
| 2019 | 234,982 | $16.21M | |
| 2020 | 175,898 | $12.22M | |
| 2021 | 167,656 | $13.76M | |
| 2022 | 216,941 | $17.76M | |
| 2023 | 244,719 | $20.49M | |
| 2024incomplete | 197,619 | $13.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 39% | 166,433 | 146,378 | $42.69M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 7.6% | 35,736 | 33,504 | $8.24M |
| 80053 | Comprehensive metabolic panel | 6.5% | 81,940 | 75,325 | $7.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 16,066 | 15,229 | $4.69M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.0% | 41,009 | 38,734 | $4.34M |
| 71045 | Radiologic examination, chest; single view | 3.5% | 50,138 | 47,115 | $3.83M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 21,793 | 19,762 | $3.70M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 16,288 | 15,688 | $2.10M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 14,910 | 14,370 | $1.90M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.7% | 18,852 | 17,988 | $1.90M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 7,114 | 6,659 | $1.65M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 8,342 | 7,837 | $1.54M |
230 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 9,025 | $1.22M |
| 81025 | 1.0% | 17,238 | $1.10M | |
| Z7502 | 1.0% | 29,014 | $1.09M | |
| 81003 | <1% | 41,820 | $915K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 87,408 | $910K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12,664 | $900K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,339 | $869K |
| 36415 | Collection of venous blood by venipuncture | <1% | 56,419 | $745K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 7,563 | $700K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 45,244 | $627K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,085 | $561K |
| 84484 | <1% | 31,100 | $540K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,754 | $539K |
| 73610 | <1% | 3,785 | $517K | |
| 73564 | <1% | 3,543 | $517K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,860 | $492K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,982 | $474K |
| 83690 | <1% | 27,490 | $469K | |
| 87275 | <1% | 4,984 | $465K | |
| 73630 | <1% | 4,822 | $424K | |
| 73130 | <1% | 3,851 | $421K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,542 | $407K |
| 83880 | <1% | 11,980 | $406K | |
| 76801 | <1% | 4,291 | $355K | |
| 82962 | <1% | 11,020 | $351K | |
| 73030 | <1% | 3,465 | $349K | |
| 72040 | <1% | 2,499 | $327K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,687 | $314K |
| 72100 | <1% | 4,028 | $309K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,174 | $307K |
| 87070 | <1% | 3,631 | $299K | |
| 74018 | <1% | 2,729 | $289K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,578 | $270K |
| 73110 | <1% | 2,312 | $261K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,213 | $259K |
| J3490 | Unclassified drugs | <1% | 43,969 | $257K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,386 | $250K |
| 85610 | <1% | 35,257 | $222K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 645 | $201K |
| 81001 | <1% | 15,655 | $197K | |
| 84703 | <1% | 18,570 | $185K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,526 | $180K |
| 70486 | <1% | 1,504 | $172K | |
| 99199 | Unlisted special service, procedure or report | <1% | 7,417 | $171K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,273 | $161K |
| 83735 | <1% | 13,903 | $146K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,628 | $145K |
| 73080 | <1% | 1,298 | $140K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,944 | $139K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,878 | $128K |
| 84702 | <1% | 5,935 | $113K | |
| 87077 | <1% | 3,718 | $106K | |
| Z7610 | <1% | 12,235 | $105K | |
| 81002 | <1% | 2,654 | $102K | |
| 85730 | <1% | 14,610 | $101K | |
| 86900 | <1% | 5,117 | $95K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 374 | $92K |
| 93971 | <1% | 2,146 | $92K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 21,347 | $88K |
| 73590 | <1% | 1,106 | $88K | |
| 73562 | <1% | 713 | $87K | |
| 73090 | <1% | 963 | $84K | |
| 0250 | <1% | 56,953 | $79K | |
| 72131 | <1% | 758 | $77K | |
| 0353U | <1% | 718 | $74K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,907 | $70K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,496 | $69K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,192 | $63K |
| 87040 | <1% | 4,890 | $59K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,499 | $57K |
| 83605 | <1% | 4,404 | $54K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,744 | $53K |
| 74019 | <1% | 447 | $53K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 701 | $49K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,927 | $47K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,863 | $47K |
| 59025 | Fetal non-stress test | <1% | 1,240 | $45K |
| 73502 | <1% | 652 | $43K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,631 | $41K |
| 76870 | <1% | 422 | $41K | |
| 0270 | <1% | 27,916 | $39K | |
| 86850 | <1% | 2,582 | $37K | |
| 96376 | <1% | 3,693 | $36K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,070 | $35K |
| 0260 | <1% | 310 | $35K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 489 | $34K |
| 87430 | <1% | 2,813 | $34K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,059 | $33K |
| 90715 | <1% | 2,394 | $32K | |
| 73140 | <1% | 206 | $32K | |
| 93970 | <1% | 480 | $32K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,300 | $31K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 548 | $29K |
| 85379 | <1% | 2,539 | $28K | |
| 87186 | <1% | 3,377 | $28K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,071 | $27K |
| 71101 | <1% | 167 | $24K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 297 | $21K |
| 71250 | <1% | 291 | $21K | |
| 87088 | <1% | 4,244 | $20K | |
| 74022 | <1% | 164 | $20K | |
| 0710 | <1% | 321 | $20K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 226 | $19K |
| 87276 | <1% | 4,982 | $18K | |
| 86901 | <1% | 5,153 | $17K | |
| 0320 | <1% | 594 | $17K | |
| 71010 | <1% | 287 | $17K | |
| 85027 | <1% | 1,267 | $15K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 476 | $14K |
| 82803 | <1% | 524 | $14K | |
| 94760 | <1% | 4,201 | $14K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,898 | $13K |
| 72170 | <1% | 166 | $13K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 627 | $12K |
| 12001 | <1% | 183 | $12K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,166 | $12K |
| 87420 | <1% | 1,465 | $11K | |
| 82550 | <1% | 801 | $11K | |
| 71111 | <1% | 69 | $11K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 75 | $11K |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 251 | $10K |
| 96367 | <1% | 560 | $9K | |
| 86140 | <1% | 1,056 | $8K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 100 | $8K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,304 | $8K |
| 0300 | <1% | 270 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,855 | $7K |
| 82010 | <1% | 236 | $6K | |
| 70490 | <1% | 29 | $6K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,931 | $6K |
| 70496 | <1% | 54 | $6K | |
| 36430 | <1% | 49 | $6K | |
| 84439 | <1% | 718 | $5K | |
| 0636 | <1% | 802 | $5K | |
| 73060 | <1% | 77 | $5K | |
| 80076 | <1% | 451 | $5K | |
| 70498 | <1% | 54 | $5K | |
| 82140 | <1% | 354 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 291 | $5K |
| 73620 | <1% | 38 | $5K | |
| 0510 | <1% | 88 | $5K | |
| 84100 | <1% | 723 | $5K | |
| 72072 | <1% | 131 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 251 | $4K |
| 86308 | <1% | 132 | $4K | |
| 76775 | <1% | 24 | $4K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 307 | $4K |
| 71020 | <1% | 41 | $4K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 646 | $3K |
| 73600 | <1% | 13 | $3K | |
| 87210 | <1% | 74 | $3K | |
| 94664 | <1% | 798 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,893 | $3K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 923 | $3K |
| 87147 | <1% | 620 | $2K | |
| 29126 | <1% | 101 | $2K | |
| 73552 | <1% | 26 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 607 | $2K |
| 29125 | <1% | 40 | $2K | |
| 85652 | <1% | 540 | $2K | |
| 27502 | <1% | 19 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 671 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 379 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 287 | $2K |
| 36600 | <1% | 338 | $2K | |
| A9270 | Non-covered item or service | <1% | 932 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 558 | $2K |
| 99070 | <1% | 1,822 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 88 | $2K |
| 82247 | <1% | 465 | $2K | |
| 0258 | <1% | 560 | $1K | |
| 87205 | <1% | 161 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 247 | $1K |
| 72128 | <1% | 13 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,471 | $1K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 510 | $1K |
| 12011 | <1% | 27 | $1K | |
| 73120 | <1% | 33 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 338 | $945.81 |
| 87561 | <1% | 72 | $915.53 | |
| 99072 | <1% | 1,305 | $885.05 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 720 | $855.46 |
| 70360 | <1% | 15 | $854.84 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 248 | $839.68 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 284 | $810.33 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 80 | $804.55 |
| 84075 | <1% | 32 | $802.94 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 31 | $801.05 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,793 | $737.56 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 94 | $736.29 |
| 70491 | <1% | 12 | $664.41 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 15 | $655.50 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 46 | $494.78 |
| 94644 | <1% | 51 | $491.84 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 212 | $490.64 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 41 | $474.50 |
| 0272 | <1% | 217 | $474.15 | |
| 82728 | <1% | 74 | $458.62 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 83 | $383.76 |
| 72070 | <1% | 38 | $300.70 | |
| 86920 | <1% | 42 | $286.59 | |
| 84704 | <1% | 41 | $223.80 | |
| 27610 | <1% | 12 | $220.43 | |
| 82248 | <1% | 99 | $209.78 | |
| 29515 | <1% | 42 | $203.63 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 28 | $175.44 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 16 | $173.02 |
| 90714 | <1% | 62 | $170.50 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 22 | $91.78 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 15 | $91.02 |
| 97116 | <1% | 34 | $75.05 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 80 | $70.58 |
| 82565 | <1% | 16 | $51.21 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 239 | $49.60 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 13 | $43.52 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 61 | $34.65 |
| 82310 | <1% | 21 | $30.23 | |
| 84450 | <1% | 12 | $11.85 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 12 | $10.09 |
| 0370 | <1% | 39 | $8.70 | |
| 0301 | 0% | 120 | $0.00 | |
| 0307 | 0% | 26 | $0.00 | |
| 0306 | 0% | 14 | $0.00 | |
| 0350 | 0% | 13 | $0.00 | |
| 0305 | 0% | 154 | $0.00 | |
| 0206 | 0% | 43 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 16 | $0.00 |
| 0730 | 0% | 68 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 98 | $0.00 |
| 0760 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.